6.70
Schlusskurs vom Vortag:
$6.78
Offen:
$6.66
24-Stunden-Volumen:
388.63K
Relative Volume:
0.65
Marktkapitalisierung:
$405.87M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-117.81M
KGV:
-3.5638
EPS:
-1.88
Netto-Cashflow:
$74.30M
1W Leistung:
-4.15%
1M Leistung:
-26.37%
6M Leistung:
+63.41%
1J Leistung:
+119.67%
Omeros Corporation Stock (OMER) Company Profile
Firmenname
Omeros Corporation
Sektor
Branche
Telefon
206-676-5000
Adresse
201 ELLIOTT AVENUE WEST, SEATTLE, WA
Vergleichen Sie OMER mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
OMER
Omeros Corporation
|
6.70 | 405.87M | 0 | -117.81M | 74.30M | -1.88 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Omeros Corporation Stock (OMER) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2024-12-23 | Eingeleitet | D. Boral Capital | Buy |
2024-11-14 | Eingeleitet | Rodman & Renshaw | Buy |
2022-12-08 | Herabstufung | UBS | Buy → Neutral |
2022-11-08 | Herabstufung | BofA Securities | Neutral → Underperform |
2022-06-08 | Herabstufung | BofA Securities | Buy → Neutral |
2021-10-08 | Herabstufung | JP Morgan | Neutral → Underweight |
2021-10-01 | Herabstufung | Maxim Group | Buy → Hold |
2021-10-01 | Herabstufung | Wedbush | Neutral → Underperform |
2021-09-27 | Eingeleitet | JP Morgan | Neutral |
2021-02-01 | Eingeleitet | UBS | Buy |
2020-10-20 | Eingeleitet | BofA Securities | Buy |
2020-08-21 | Bestätigt | H.C. Wainwright | Buy |
2020-08-14 | Bestätigt | Maxim Group | Buy |
2019-05-06 | Eingeleitet | Cantor Fitzgerald | Overweight |
2018-07-12 | Eingeleitet | Seaport Global Securities | Buy |
2018-03-23 | Herabstufung | Wedbush | Outperform → Neutral |
2018-03-05 | Herabstufung | Needham | Buy → Hold |
2017-11-08 | Eingeleitet | H.C. Wainwright | Buy |
2017-05-11 | Herabstufung | Cantor Fitzgerald | Buy → Neutral |
2017-03-17 | Bestätigt | Maxim Group | Buy |
2017-03-17 | Bestätigt | Needham | Buy |
2016-11-16 | Bestätigt | Wedbush | Outperform |
2016-11-10 | Bestätigt | Needham | Buy |
2016-08-10 | Bestätigt | Maxim Group | Buy |
2016-06-03 | Eingeleitet | Cantor Fitzgerald | Buy |
2016-03-02 | Bestätigt | Needham | Buy |
2016-02-29 | Bestätigt | Wedbush | Outperform |
2015-11-11 | Bestätigt | Needham | Buy |
2015-08-18 | Bestätigt | WBB Securities | Strong Buy |
2015-08-10 | Eingeleitet | ROTH Capital | Buy |
Alle ansehen
Omeros Corporation Aktie (OMER) Neueste Nachrichten
Omeros Co. (NASDAQ:OMER) Position Increased by Alliancebernstein L.P. - Defense World
Franklin Resources Inc. Makes New Investment in Omeros Co. (NASDAQ:OMER) - Defense World
Omeros Co. (NASDAQ:OMER) Shares Sold by ExodusPoint Capital Management LP - The AM Reporter
Vanguard Group Inc. Reduces Stock Position in Omeros Co. (NASDAQ:OMER) - Defense World
Raymond James Financial Inc. Invests $124,000 in Omeros Co. (NASDAQ:OMER) - Defense World
D. Boral Capital Reiterates Buy Rating for Omeros (NASDAQ:OMER) - Defense World
Corebridge Financial Inc. Sells 2,100 Shares of Omeros Co. (NASDAQ:OMER) - Defense World
Omeros' New Leukemia Drug Team Ignites Hope For Cancer FightOmeros (NASDAQ:OMER) - Benzinga
Omeros Announces the Omeros Oncology Clinical Steering Committee - GuruFocus
Omeros forms steering committee for leukemia treatment By Investing.com - Investing.com South Africa
Omeros announces oncology clinical steering committee to help guide proprietary Oncotox-AML clinical program - marketscreener.com
Omeros forms steering committee for leukemia treatment - Investing.com
Omeros Announces the Omeros Oncology Clinical Steering Committee for AML to Help Guide Omeros’ Proprietary OncotoX-AML Clinical Program - The Joplin Globe
Omeros (NASDAQ:OMER) Downgraded by StockNews.com to Sell - Defense World
Omeros Corporation To Introduce Its Proprietary T-CAT™ Program for the Treatment of Multidrug-Resistant Pathogens in Plenary Session at Upcoming European Congress on Infectious Diseases - Yahoo Finance
Revolutionary T-CAT Platform Takes Aim at $135B Antibiotic Crisis with 99% Kill Rate - Stock Titan
It makes sense and dollars to buy Omeros Corporation (OMER) stock - Sete News
(OMER) Technical Data - news.stocktradersdaily.com
FY2025 EPS Estimates for Omeros Reduced by Cantor Fitzgerald - Defense World
Omeros (NASDAQ:OMER) Upgraded to Hold at StockNews.com - The AM Reporter
Omeros (NASDAQ:OMER) Earns "Buy" Rating from D. Boral Capital - MarketBeat
Omeros Co. (NASDAQ:OMER) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
4,671 Shares in Omeros Co. (NASDAQ:OMER) Acquired by Quantbot Technologies LP - Defense World
Omeros (NASDAQ:OMER) Receives “Hold” Rating from Needham & Company LLC - Defense World
Omeros Corporation’s Earnings Call Highlights Progress and Challenges - TipRanks
Omeros Corporation (NASDAQ:OMER) Q4 2024 Earnings Call Transcript - Insider Monkey
Omeros (OMER) Exceeds Q4 EPS Expectations, Reports Cash Decline - GuruFocus
Omeros: Q4 Earnings Snapshot - CT Insider
Omeros Corp (OMER) Q4 2024 Earnings Call Highlights: Navigating Financial Challenges with ... - Yahoo
Omeros Corp (OMER) Q4 2024 Earnings Call Highlights: Navigating Financial Challenges with Strategic Initiatives - GuruFocus
Omeros Corporation Reports 2024 Financial Results - TipRanks
Earnings call transcript: Omeros Q4 2024 sees narrower EPS loss, stock climbs - Investing.com Canada
Earnings call transcript: Omeros Q4 2024 sees narrower EPS loss, stock climbs By Investing.com - Investing.com South Africa
Omeros beats Q4 earnings estimates, shares rise 5% By Investing.com - Investing.com South Africa
Omeros beats Q4 earnings estimates, shares rise 5% - Investing.com Australia
OMEROS CORP SEC 10-K Report - TradingView
Omeros reports Q4 EPS (54c), consensus (71c) - TipRanks
Omeros Corporation Reports Fourth Quarter and Year-End 2024 Financial Results - Yahoo Finance
Omeros (OMER) to Release Quarterly Earnings on Monday - Defense World
Top Wall Street Forecasters Revamp Omeros Price Expectations Ahead Of Q4 Earnings - Benzinga
In the Green: Omeros Corporation (OMER) Closes at 8.52, Up/Down -6.99 from Previous Day - DWinneX
Omeros Corporation (OMER) Stock: A 52-Week Tale of Drops and Gains - The InvestChronicle
Trend Tracker for (OMER) - news.stocktradersdaily.com
Strong Buy Rating for Omeros Corporation Driven by Promising Narsoplimab Prospects and Strategic Advancements - TipRanks
Omeros Corporation to Announce Fourth Quarter and Year-end Financial Results on March 31, 2025 - Joplin Globe
Omeros Earnings Preview: Key Metrics to Watch in Q4 and Full Year Report - Stock Titan
Finanzdaten der Omeros Corporation-Aktie (OMER)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):